Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ANAPTYSBIO, INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
16.7
10
5
8
75
63.2
10.3
17.2
91.3
235
Research and development
15.4
29.4
56.2
99.3
80
98.5
88.8
132
164
136
General and administrative
4.29
9.34
15.5
16.1
18.9
21.5
36.6
41.9
13.6
11.3
Operating expenses
19.7
38.8
71.7
115
98.9
120
125
182
25.1
7.7
Operating income
-3.03
-28.8
-66.7
-107
-23.9
-56.8
-115
-164
66.2
227
Interest expense
0.46
1.78
1.65
1.04
0
0
Interest income
0.13
1.62
6.69
11
3.96
0.43
7.55
18.9
15.1
9.81
Other non-operating income
-1.23
-1.29
4.87
9.94
3.95
-0.98
-13.5
0.79
-35
-64.6
Pre-tax income
-4.26
-30.1
-61.8
-97.5
-19.9
-57.8
-129
-164
31.1
162
Income tax
0
0
-0.19
-0.15
0
0
0.02
-0
0.16
0.77
Income from continuing operations
31
162
Net income
-4.26
-30.1
-61.7
-97.3
-19.9
-57.8
-129
-164
-145
-13.2
EBITDA
-2.79
-28.6
-66.4
-107
-23.3
-56.2
-114
-164
66.2
227
EPS, basic
-1.62
-1.52
-2.50
-3.60
-0.73
-2.11
-4.57
-6.08
-5.12
-0.46
EPS, diluted
-1.62
-1.52
-2.50
-3.60
-0.73
-2.11
-4.57
-6.08
-4.92
-0.44
Shares, basic (weighted)
2.64
19.8
24.7
27.1
27.3
27.4
28.2
26.9
28.4
28.8
Shares, diluted (weighted)
2.64
19.8
24.7
27.1
27.3
27.4
28.2
26.9
29.5
30.2
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
51.2
81.2
114
171
250
496
71.3
36
23.1
138
Short-term investments
0
167
313
203
143
52.4
370
355
262
73.4
Receivables
1.23
0
0
0
0
0.88
1.42
6.85
40.8
33.9
Other current assets
1.63
2.69
6.96
3.51
2.91
4.9
4.55
9.08
1.18
0
Total current assets
58.2
253
434
378
397
554
447
407
432
350
Property, plant and equipment
0.47
0.67
1.45
1.62
1.78
2.28
2.09
2.1
0.13
0.11
Lease right-of-use assets
1.4
0.34
19.6
17.9
16.2
14.4
12.5
Long-term investments
0
75.9
73.1
54.3
17.5
67.1
143
27
35.5
0
Other non-current assets
0.05
0.15
1.48
0.26
0.26
0.26
0.26
0.26
0.26
Total assets
62.2
329
509
435
417
643
610
452
484
364
Accounts payable
2.28
2.32
5.44
16.2
4.22
1.74
2.78
4.7
4
3.87
Accrued liabilities
3.43
4.88
8.76
11.1
15.3
12.9
21.6
31
39.5
32.7
Total current liabilities
5.71
14.1
21.8
29.5
19.8
16.1
26.1
37.4
45.4
38.6
Lease liabilities
0.65
0
19.5
17.8
16
14.1
12
Other non-current liabilities
0.8
0.65
0
Total liabilities
100
21.8
22.6
30.2
19.8
287
348
364
413
327
Paid-in capital
16.7
393
633
649
661
679
718
703
830
810
Retained earnings
-54.9
-85
-147
-244
-264
-322
-450
-614
-759
-773
Other comprehensive income
0
-0.43
-0.22
0.34
-0
-0.42
-5.25
-0.8
0.31
-0.02
Shareholders' equity
-38.2
308
486
405
397
356
262
88.1
70.9
37.2
Total equity
-38.2
308
486
405
397
356
262
88.1
70.9
37.2
Total liabilities and equity
62.2
329
509
435
417
643
610
452
484
364
Shares outstanding
2.65
23.8
26.9
27.3
27.4
27.6
28.5
26.6
30.5
28
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-4.26
-30.1
-61.7
-97.3
-19.9
-57.8
-129
-164
-145
-13.2
Depreciation and amortization
0.23
0.18
0.32
0.51
0.56
0.62
0.68
0.65
0.02
0.02
Stock-based compensation
1.16
4.38
15.3
27.4
33.2
7.22
3.77
Deferred income tax
0
0
Change in payables
1.25
2.22
7.08
13.2
-7.69
-4.74
9.7
10.9
-33.8
-87.3
Cash from operations
-9.03
-19.4
-48.5
-69.5
-14.2
-45.9
-73.6
-121
-135
19.7
Capital expenditures
-0.05
-0.29
-1.06
-0.81
-0.57
-1.37
-0.36
-0.81
-0.36
-0.09
Purchases of investments
0
-291
-348
-252
-195
-119
-803
-304
-380
-196
Cash from investing
-0.05
-243
-142
131
94.5
38.8
-395
145
31.4
228
Stock issued
0
293
227
3.01
0.5
2.55
11.8
2.47
6.47
14.3
Share buybacks
-0
0
0
0
0
-50
-0.46
-68.6
Cash from financing
8.63
292
223
-4.49
-0.88
252
44
-59.3
127
-133
Net change in cash
-0.45
30
32.4
57.4
79.4
245
-424
-35.3
23.1
115
Free cash flow
-9.08
-19.7
-49.6
-70.3
-14.7
-47.3
-74
-122
-136
19.6
Interest paid
0.35
1.09
1.04
0.42
0
0
0
0
42.1
80
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $51.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
94.6%
Operating income / revenue.
EBITDA margin
94.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
64.0%
Pre-tax income / revenue.
Net margin
-11.5%
Net income / revenue.
FCF margin
1.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
1.9%
Cash from operations / revenue.
Effective tax rate
0.5%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
-210.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-8.1%
Net income / average total assets.
Stock-based pay / revenue
3.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.0%
Capital expenditures / revenue.
D&A / revenue
0.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
157.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
183.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
25.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y
243.0%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
242.9%
EBITDA vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-47.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-47.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-37.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-24.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-15.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-2.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
2.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
2.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.58x
Current assets / current liabilities.
Quick ratio
7.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.87x
(Cash + short-term investments) / current liabilities.
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.93
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$8.10
Revenue / diluted weighted shares.
FCF per share
$0.15
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.16
Cash from operations / diluted weighted shares.
Book value per share
$0.44
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Share buybacks / free cash flow, when free cash flow is positive.
Valuation
Metric
Value
How it is calculated
Market cap
$1.51B
Share price x shares outstanding.
Enterprise value
$1.22B
Market cap + total debt - cash - short-term investments.
P/S
6.50x
Market cap / revenue.
P/B
118x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
118x
Market cap / tangible book value, when positive.
P/FCF
342x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
337x
Market cap / cash from operations, when positive.
EV/Sales
5.27x
Enterprise value / revenue.
EV/EBIT
5.57x
Enterprise value / operating income, when both are positive.
EV/EBITDA
5.57x
Enterprise value / EBITDA, when both are positive.
EV/FCF
278x
Enterprise value / free cash flow, when both are positive.
FCF yield
0.3%
Free cash flow / market cap.
Earnings yield
-1.8%
Net income / market cap (the inverse of P/E).
Shareholder yield
4.3%
(Dividends paid + share buybacks) / market cap.
What was ANAPTYSBIO, INC's revenue in fiscal 2025?
ANAPTYSBIO, INC reported revenue of $234.6M for fiscal 2025, 157% higher than the year before.
Was ANAPTYSBIO, INC profitable in fiscal 2025?
No. It reported a net loss of $13.2M.
How much free cash flow did ANAPTYSBIO, INC generate in fiscal 2025?
Cash from operations of $19.7M minus capital expenditures of $87.0K left free cash flow of $19.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.